<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34287852</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>17</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1365-4632</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>61</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
            </PubDate>
          </JournalIssue>
          <Title>International journal of dermatology</Title>
          <ISOAbbreviation>Int J Dermatol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Mucha-Habermann disease: a pediatric case report and proposal of a risk score.</ArticleTitle>
        <Pagination>
          <StartPage>401</StartPage>
          <EndPage>409</EndPage>
          <MedlinePgn>401-409</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/ijd.15770</ELocationID>
        <Abstract>
          <AbstractText>Febrile ulceronecrotic Mucha-Habermann disease (FUMHD) is a rare inflammatory dermatological disease. A case of a 13-year-old boy with FUMHD possibly triggered by mycoplasma infection is presented. Based on FUMHD cases identified in a MEDLINE literature search, demographic, treatment, and outcome data were analyzed. An FUMHD mortality risk score is proposed based on the likelihood ratios of risk factors for a fatal outcome. Our FUMHD case had marked leukopenia and thrombocytopenia at admission. He recovered without systemic immunosuppressive treatment. Literature review revealed 119 FUMHD cases. Overall lethality was 14/119 (12%, CI 6-17%), and lethality in children was lower (1/54, 2%, CI 0-6%) compared to adults (13/65, 20%, CI 11-31%). Risk factors for a fatal outcome (likelihood ratio; P) were sepsis (24.97, P &lt; 0.001), adult vs. pediatric patient age (11.19; P = 0.001), systemic involvement (19.97, P &lt; 0.001), and mucosal involvement (4.58; P = 0.032). The proposed FUMHD mortality risk score = Age/10 + 4 + 4 (if systemic involvement) + 1 (if mucosal involvement) was discriminative (sensitivity 93%, specificity 77%). In FUMHD, immune-suppressive treatment intensity should be balanced against the mortality risk, as infectious complications are a frequent cause of death.</AbstractText>
          <CopyrightInformation>© 2021 The Authors. International Journal of Dermatology published by Wiley Periodicals LLC on behalf of the International Society of Dermatology.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Blohm</LastName>
            <ForeName>Martin Ernst</ForeName>
            <Initials>ME</Initials>
            <Identifier Source="ORCID">0000-0003-3873-0634</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Paediatrics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Division of Neonatology and Paediatric Intensive Care, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ebenebe</LastName>
            <ForeName>Chinedu Ulrich</ForeName>
            <Initials>CU</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Paediatrics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Division of Neonatology and Paediatric Intensive Care, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rau</LastName>
            <ForeName>Cornelius</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Paediatrics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Division of Neonatology and Paediatric Intensive Care, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Escherich</LastName>
            <ForeName>Carolin</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Paediatric Oncology, Haematology and Clinical Immunology, University Hospital Düsseldorf, Düsseldorf, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Johannsen</LastName>
            <ForeName>Jessika</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Paediatrics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Escherich</LastName>
            <ForeName>Gabriele</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Paediatric Haematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Driemeyer</LastName>
            <ForeName>Joenna</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Paediatrics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nagel</LastName>
            <ForeName>Philipp Daniel</ForeName>
            <Initials>PD</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Paediatrics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Division of Neonatology and Paediatric Intensive Care, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kobbe</LastName>
            <ForeName>Robin</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Infectious Diseases, First Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lütgehetmann</LastName>
            <ForeName>Marc</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Medical Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lennartz</LastName>
            <ForeName>Maximilian</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Booken</LastName>
            <ForeName>Nina</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology and Venereology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schneider</LastName>
            <ForeName>Stefan Werner</ForeName>
            <Initials>SW</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology and Venereology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Singer</LastName>
            <ForeName>Dominique</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Paediatrics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Division of Neonatology and Paediatric Intensive Care, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>07</Month>
          <Day>20</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Int J Dermatol</MedlineTA>
        <NlmUniqueID>0243704</NlmUniqueID>
        <ISSNLinking>0011-9059</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006561" MajorTopicYN="Y">Herpes Simplex</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017514" MajorTopicYN="Y">Pityriasis Lichenoides</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013921" MajorTopicYN="Y">Thrombocytopenia</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>21</Day>
          <Hour>13</Hour>
          <Minute>9</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34287852</ArticleId>
        <ArticleId IdType="doi">10.1111/ijd.15770</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>References</Title>
        <Reference>
          <Citation>Nofal A, Assaf M, Alakad R, et al. Febrile ulceronecrotic Mucha-Habermann disease: proposed diagnostic criteria and therapeutic evaluation. Int J Dermatol 2016; 55: 729-738.</Citation>
        </Reference>
        <Reference>
          <Citation>Geller L, Antonov NK, Lauren CT, et al. Pityriasis lichenoides in childhood: review of clinical presentation and treatment options. Pediatr Dermatol 2015; 32: 579-592.</Citation>
        </Reference>
        <Reference>
          <Citation>Maranda EL, Smith M, Nguyen AH, et al. Phototherapy for pityriasis lichenoides in the pediatric population: a review of the published literature. Am J Clin Dermatol 2016; 17: 583-591.</Citation>
        </Reference>
        <Reference>
          <Citation>Meziane L, Caudron A, Dhaille F, et al. Febrile ulceronecrotic Mucha-Habermann disease: treatment with infliximab and intravenous immunoglobulins and review of the literature. Dermatology 2012; 225: 344-348.</Citation>
        </Reference>
        <Reference>
          <Citation>Kreuter A, Knispel S, Wieland U, et al. Complete resolution of febrile ulceronecrotic Mucha-Habermann disease following infliximab therapy. J Dtsch Dermatol Ges 2016; 14: 184-186.</Citation>
        </Reference>
        <Reference>
          <Citation>Orenstein LAV, Coughlin CC, Flynn AT, et al. Severe Mucha-Habermann-like ulceronecrotic skin disease in T-cell acute lymphoblastic leukemia responsive to basiliximab and stem cell transplant. Pediatr Dermatol 2017; 34: e265-e270.</Citation>
        </Reference>
        <Reference>
          <Citation>Alratrout J, Alshammasi F, Ansari N. Febrile ulceronecrotic Mucha-Habermann disease in an 8-year-old boy responding to methotrexate. Int J Dermatol 2016; 55: 1205-1209.</Citation>
        </Reference>
        <Reference>
          <Citation>Arellano Lorca J, Yáñez Silva I, Soto Vilches F, et al. Enfermedad de Mucha-Habermann febril ulceronecrótica con respuesta favorable a minociclina, a propósito de un caso: report of one case [Febrile ulceronecrotic Mucha-Habermann disease]. Rev Med Chil 2016; 144: 1214-1217.</Citation>
        </Reference>
        <Reference>
          <Citation>Avshalumova L, Richardson B, Miller R. Pityriasis lichenoides chronica presenting with bilateral palmoplantar involvement. Cutis 2016; 97: 345;347;358.</Citation>
        </Reference>
        <Reference>
          <Citation>Bhide DS, Tulpule MS, Pethe SV. A case of febrile ulceronecrotic Mucha-Habermann disease with comorbidities. Indian J Dermatol Venereol Leprol 2019; 85: 660-663.</Citation>
        </Reference>
        <Reference>
          <Citation>Bordel Gómez M, Santos Durán JC, Sánchez Estella J, et al. Pitiriasis liquenoide y varioliforme aguda (enfermedad de Mucha-Haberman) [Pityriasis lichenoides et varioliformis acuta (Mucha-Habermann disease)]. An Pediatr 2007; 66: 98-100.</Citation>
        </Reference>
        <Reference>
          <Citation>Bulur I, Kaya Erdoğan H, Nurhan Saracoglu Z, et al. Methotrexate treatment in children with febrile ulceronecrotic Mucha-Habermann disease: case report and literature review. Case Rep Dermatol Med 2015; 2015: 357973.</Citation>
        </Reference>
        <Reference>
          <Citation>Cornelison RL Jr, Knox JM, Everett MA. Methotrexate for the treatment of Mucha-Habermann disease. Arch Dermatol 1972; 106: 507-508.</Citation>
        </Reference>
        <Reference>
          <Citation>Dupin A, Bosset D, Atger L, et al. Maladie de Mucha-Habermann fébrile et ulcéronécrotique [Febrile ulceronecrotic Mucha-Habermann disease]. Arch Pediatr 2016; 23: 82-85.</Citation>
        </Reference>
        <Reference>
          <Citation>Edwards BL, Bonagura VR, Valacer DJ, et al. Mucha-Habermann's disease and arthritis: possible association with reactivated Epstein-Barr virus infection. J Rheumatol 1989; 16: 387-389.</Citation>
        </Reference>
        <Reference>
          <Citation>Ellsworth JE, Cassidy JT, Ragsdale CG, et al. Mucha-Habermann disease in children−the association with rheumatic diseases. J Rheumatol 1982; 9: 319-324.</Citation>
        </Reference>
        <Reference>
          <Citation>Fongue J, Amatore F, Benzaquen M, et al. Febrile ulceronecrotic Mucha-Habermann disease after levamisole-adulterated cocaine use: an unusual case. Clin Exp Dermatol 2018; 43: 846-848.</Citation>
        </Reference>
        <Reference>
          <Citation>Gross DJ, Metheny RS, Keeran MG. A widespread hemorrhagic and crusted eruption of recent onset. Pityriasis lichenoides et varioliformis acuta (PLEVA) (Mucha-Habermann disease). Arch Dermatol 1993; 129: 365-368.</Citation>
        </Reference>
        <Reference>
          <Citation>Hermanns-Lê T, Piérard GE. Medullary CD30+ T cell lymphoma with eosinophilia and hyper-IgE supervening during the relentless course of pityriasis lichenoides. Dermatology 2000; 200: 170-172.</Citation>
        </Reference>
        <Reference>
          <Citation>Hollander A, Grots IA. Mucha-Habermann disease following estrogen-progesterone therapy. Arch Dermatol 1973; 107: 465.</Citation>
        </Reference>
        <Reference>
          <Citation>Kawamura K, Tsuji T, Kuwabara Y. Mucha-Habermann disease-like eruptions due to Tegafur. J Dermatol 1999; 26: 164-167.</Citation>
        </Reference>
        <Reference>
          <Citation>Kobayasi T. Papulosis lymphomatoides, en variant af pityriasis lichenoides varioliformis acuta (Mucha-Habermann) [Lymphomatoid papulosis, a variant of acute pityriasis lichenoides varioliformis (Muncha-Habermann)]. Ugeskr Laeger 1974; 136: 156-158.</Citation>
        </Reference>
        <Reference>
          <Citation>Korppi M, Tenhola S, Hollmen A. Mucha-Habermann disease: a diagnostic possibility for prolonged fever associated with systemic and skin symptoms. Acta Paediatr 1993; 82: 627-629.</Citation>
        </Reference>
        <Reference>
          <Citation>Lalevee S, Ortonne N, Hotz C, et al. Febrile ulceronecrotic Mucha Habermann disease mimicking aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma: a diagnostic challenge. Eur J Dermatol 2018; 28: 834-835.</Citation>
        </Reference>
        <Reference>
          <Citation>Lode HN, Döring P, Lauenstein P, et al. Febrile ulceronecrotic Mucha-Habermann disease following suspected hemorrhagic chickenpox infection in a 20-month-old boy. Infection 2015; 43: 583-588.</Citation>
        </Reference>
        <Reference>
          <Citation>MacKinnon JL. Ultraviolet light treatment of a patient with pityriasis lichenoides et varioliformis acuta (Mucha-Habermann disease). A case report. Phys Ther 1986; 66: 1542-1543.</Citation>
        </Reference>
        <Reference>
          <Citation>Maria Sălăvăstru C, Severin E, Moisa M, et al. Extreme dermatology-the intensive care skills of dermatologists in three case presentations of acute skin failure. Acta Dermatovenerol Croat 2014; 22: 44-47.</Citation>
        </Reference>
        <Reference>
          <Citation>McDaniel RK, White JW Jr, Edwards PA. Mucha-Habermann's disease with oral lesions. Oral Surg Oral Med Oral Pathol 1982; 53: 596-601.</Citation>
        </Reference>
        <Reference>
          <Citation>Muller SA, Schulze TW Jr. Mucha-Habermann disease mistaken for reticulum cell sarcoma. Arch Dermatol 1971; 103: 423-427.</Citation>
        </Reference>
        <Reference>
          <Citation>Nagy E, Balogh EE. Clinical findings for the treatment of Mucha-Habermann disease (parapsoriasis varioliformis) with acridine and chinoline derivatives. Dermatologica 1959; 118: 391-396.</Citation>
        </Reference>
        <Reference>
          <Citation>Nishimura M, Matsuda T, Hori Y. Mucha-Habermann disease resolves after tonsillectomy. Int J Dermatol 1991; 30: 896-897.</Citation>
        </Reference>
        <Reference>
          <Citation>Bica BE, de Barros MG, Spingola C Jr. Mucha-Habermann disease. Rev Bras Reumatol 2013; 53: 314-317.</Citation>
        </Reference>
        <Reference>
          <Citation>Griffith-Bauer K, Leitenberger SL, Krol A. Febrile ulceronecrotic Mucha-Habermann disease: two cases with excellent response to methotrexate. Pediatr Dermatol 2015; 32: e307-e308.</Citation>
        </Reference>
        <Reference>
          <Citation>Nofal A, Alakad R, Assaf M, et al. A fatal case of febrile ulceronecrotic Mucha-Habermann disease in a child. JAAD Case Rep 2016; 2: 181-185.</Citation>
        </Reference>
        <Reference>
          <Citation>Roenigk HH Jr. Pityriasis lichenoides et varioliformis acuta (Mucha-Habermann). Arch Dermatol 1971; 104: 102-103.</Citation>
        </Reference>
        <Reference>
          <Citation>Rupp E, Blaese C. [Pityriasis lichenoides et varioliformis acuta Mucha-Habermann]. Z Haut Geschlechtskr 1957; 23: 238-241.</Citation>
        </Reference>
        <Reference>
          <Citation>Szodoray L. Die nosologische Lage der Mucha-Habermann'schen Krankheit [Nosology of the Mucha-Habermann disease]. Z Haut Geschlechtskr 1972; 47: 111-114.</Citation>
        </Reference>
        <Reference>
          <Citation>Taylor CR, Gandhi RT, Handwerker J, et al. Case records of the Massachusetts General Hospital. Case 34-2009. A 20-year-old man with sore throat, fever, and rash. N Engl J Med 2009; 361: 1787-1796.</Citation>
        </Reference>
        <Reference>
          <Citation>Torinuki W. Mucha-Habermann disease in a child: possible association with measles vaccination. J Dermatol 1992; 19: 253-255.</Citation>
        </Reference>
        <Reference>
          <Citation>Verallo VM, Haserick JR. Mucha-Habermann's disease simulating lymphoma cutis. Report of two cases. Arch Dermatol 1966; 94: 295-299.</Citation>
        </Reference>
        <Reference>
          <Citation>Virdi SK, Kanwar AJ, Saikia UN. Pityriasis lichenoides with ulceronecrosis and hyperthermia: a rare variant of pityriasis lichenoides et varioliformis acuta. Indian J Dermatol Venereol Leprol 2010; 76: 172-175.</Citation>
        </Reference>
        <Reference>
          <Citation>Shavin JS, Jones TM, Aton JK, et al. Mucha-Habermann's disease in children: treatment with erythromycin. Arch Dermatol 1978; 114: 1679-1680.</Citation>
        </Reference>
        <Reference>
          <Citation>Walther H. On the modification of pityriasis lichenoides and varioliformis acuta (Mucha-Habermann type) by penicillin; with a case report on involvement of the mucosa of the penis. Hautarzt 1960; 11: 136-137.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang B, Li J, Xie HF, et al. Striking case of Febrile ulceronecrotic Mucha-Habermann disease responding to lymphoplasmapheresis and methotrexate. J Dermatol 2020; 47: e430-e431. https://doi.org/10.1111/1346-8138.15598</Citation>
        </Reference>
        <Reference>
          <Citation>Weins AB, Theiler M, Bogatu B, et al. Morbus Mucha-Habermann unter dem Bild eines Kawasaki-Syndroms. J Dtsch Dermatol Ges 2020; 18: 140-142.</Citation>
        </Reference>
        <Reference>
          <Citation>Xing C, Shen H, Xu J, et al. A fatal case of febrile ulceronecrotic Mucha-Habermann disease which presenting as toxic epidermal necrolysis. Indian J Dermatol 2017; 62: 675.</Citation>
        </Reference>
        <Reference>
          <Citation>Sheng N, Li Z, Su W, et al. A case of primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma misdiagnosed as febrile ulceronecrotic Mucha-Habermann disease. Acta Derm Venereol 2016; 96: 136-137.</Citation>
        </Reference>
        <Reference>
          <Citation>Schneider DT, Pütz-Dolderer J, Berrang J. Pediatric multisystemic inflammatory syndrome associated with SARS-CoV-2 infection. Dtsch Arztebl Int 2020; 117: 431.</Citation>
        </Reference>
        <Reference>
          <Citation>Terraneo L, Lava SA, Camozzi P, et al. Unusual eruptions associated with mycoplasma pneumoniae respiratory infections: review of the literature. Dermatology 2015; 231: 152-157.</Citation>
        </Reference>
        <Reference>
          <Citation>Nofal A, Nofal E. Diagnosis of febrile ulceronecrotic Mucha-Habermann disease: strict clinical criteria are imperative. J Dtsch Dermatol Ges 2016; 14: 943-946.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
